Francisco Gil-Bea
Dr. Francisco Javier Gil-Bea is an Ikerbasque Associate Professor and a founding member of Miramoon Pharma S.L.
He specializes in neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and frontotemporal degeneration (FTD). At Miramoon, he contributes to drug discovery programs targeting these debilitating conditions.
He has over 15 years of research leadership experience, from investigating lifestyle-related risk factors for AD at the Karolinska Institute in Sweden, to leading an Alzheimer’s research program at the Center for Applied Medical Research (CIMA) supported by the American Alzheimer’s Association. Since 2015, he has spearheaded pioneering research on the metabolic basis of ALS and FTD at IIS Biogipuzkoa, securing funding from public agencies and industry partners such as Roche Farma. He has authored over 60 research articles and is the inventor of two patents. He is also a member of Miaker Developments S.L.
He holds a PhD from the University of Navarra and is an Associate Professor of Pharmacology at the Public University of Navarra. He is based in Pamplona, Spain.
